KILITCH

Kilitch Drugs (India) Limited

Pharmaceutical formulations manufacturer and supplier across various dosage forms

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

kilitch.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹230.40
Market cap
809 Cr
Stock P/E
26.9
P/B
2.91
ROE (FY26)
10.9%
ROCE (FY26)
12.1%
Operating margin (FY26)
14.0%
Debt / equity (FY26)
0.32
OCF / EBITDA (FY26)
65.5%
OCF / EBITDA (3Y)
44.8%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Kilitch Drugs makes pharmaceutical formulations, including dry powders, small-volume liquid ampoules and vials, at its Navi Mumbai plant and sells them in India and export markets, with a foothold in several African countries.

Company snapshot

94thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales41 Cr32 Cr45 Cr33 Cr47 Cr56 Cr61 Cr43 Cr49 Cr54 Cr90 Cr45 Cr
Operating expenses (approx.)33 Cr30 Cr38 Cr32 Cr41 Cr47 Cr47 Cr40 Cr44 Cr48 Cr67 Cr42 Cr
EBITDA9 Cr2 Cr7 Cr2 Cr6 Cr9 Cr15 Cr3 Cr5 Cr6 Cr22 Cr3 Cr
OPM %20.9%7.2%15.8%5.0%12.8%15.6%23.8%7.6%10.3%11.4%24.7%6.5%
Other income0.49 Cr3 Cr0.47 Cr3 Cr5 Cr2 Cr2 Cr3 Cr7 Cr2 Cr0.49 Cr3 Cr
Interest2 Cr2 Cr1 Cr2 Cr0.31 Cr1 Cr2 Cr2 Cr1 Cr1 Cr1 Cr0.88 Cr
Depreciation0.82 Cr0.81 Cr0.93 Cr0.85 Cr0.60 Cr0.81 Cr0.85 Cr0.84 Cr0.86 Cr0.94 Cr0.98 Cr1 Cr
Profit before tax7 Cr3 Cr5 Cr2 Cr10 Cr8 Cr14 Cr3 Cr9 Cr6 Cr20 Cr4 Cr
Tax %24.9%38.3%30.5%93.2%16.8%31.9%26.2%34.4%14.5%22.9%26.4%49.1%
Net profit5 Cr2 Cr4 Cr0.11 Cr9 Cr6 Cr10 Cr2 Cr8 Cr4 Cr15 Cr2 Cr
EPS (₹)₹2.93₹1.85₹2.24₹0.83₹5.36₹3.71₹6.47₹1.88₹4.97₹2.50₹4.24₹0.83

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales29 Cr51 Cr82 Cr53 Cr69 Cr114 Cr140 Cr154 Cr198 Cr235 CrSign in free for the trailing twelve months
Operating expenses (approx.)29 Cr46 Cr75 Cr53 Cr63 Cr104 Cr122 Cr130 Cr167 Cr199 CrSign in free for the trailing twelve months
EBITDA-0.70 Cr5 Cr7 Cr0.20 Cr5 Cr10 Cr18 Cr24 Cr31 Cr37 CrSign in free for the trailing twelve months
OPM %-2.4%10.3%8.5%0.4%7.6%9.1%12.6%15.6%15.9%15.5%Sign in free for the trailing twelve months
Other income1 Cr3 Cr4 Cr4 Cr3 Cr3 Cr3 Cr4 Cr11 Cr11 CrSign in free for the trailing twelve months
Interest—0 Cr0.38 Cr0.72 Cr0.75 Cr1 Cr5 Cr6 Cr5 Cr6 CrSign in free for the trailing twelve months
Depreciation10 Cr2 Cr2 Cr2 Cr2 Cr2 Cr4 Cr3 Cr3 Cr4 CrSign in free for the trailing twelve months
Profit before tax-9 Cr6 Cr9 Cr2 Cr5 Cr10 Cr12 Cr19 Cr34 Cr39 CrSign in free for the trailing twelve months
Tax %4.6%15.7%55.4%47.6%26.4%35.4%31.1%29.9%27.7%23.7%Sign in free for the trailing twelve months
Net profit-9 Cr5 Cr4 Cr0.84 Cr4 Cr6 Cr8 Cr14 Cr25 Cr30 CrSign in free for the trailing twelve months
EPS (₹)₹-6.72₹3.89₹2.61₹0.55₹2.37₹4.73₹6.71₹9.17₹16.60₹8.91Sign in free for the trailing twelve months
Dividend payout %————-0.5%0.0%0.0%0.0%0.0%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital13 Cr14 Cr15 Cr15 Cr15 Cr16 Cr16 Cr16 Cr16 Cr35 Cr
Reserves88 Cr98 Cr106 Cr103 Cr112 Cr124 Cr136 Cr160 Cr186 Cr245 Cr
Borrowings0.69 Cr0.92 Cr9 Cr13 Cr15 Cr20 Cr22 Cr32 Cr49 Cr89 Cr
Other liabilities11 Cr14 Cr11 Cr10 Cr59 Cr49 Cr47 Cr33 Cr63 Cr92 Cr
Total liabilities113 Cr128 Cr144 Cr143 Cr203 Cr210 Cr220 Cr240 Cr313 Cr458 Cr
Fixed assets (net)8 Cr8 Cr9 Cr9 Cr8 Cr43 Cr44 Cr42 Cr46 Cr49 Cr
CWIP0.66 Cr3 Cr20 Cr30 Cr65 Cr3 Cr4 Cr6 Cr47 Cr140 Cr
Investments53 Cr56 Cr53 Cr52 Cr60 Cr71 Cr62 Cr72 Cr72 Cr75 Cr
Inventories3 Cr3 Cr5 Cr6 Cr4 Cr5 Cr2 Cr4 Cr15 Cr12 Cr
Trade receivables15 Cr21 Cr19 Cr16 Cr23 Cr41 Cr54 Cr63 Cr85 Cr120 Cr
Cash & bank2 Cr5 Cr8 Cr3 Cr13 Cr10 Cr20 Cr19 Cr10 Cr16 Cr
Other assets32 Cr32 Cr29 Cr28 Cr31 Cr36 Cr34 Cr34 Cr38 Cr47 Cr
Total assets113 Cr128 Cr144 Cr143 Cr203 Cr210 Cr220 Cr240 Cr313 Cr458 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity1 Cr2 Cr0.29 Cr4 Cr46 Cr6 Cr3 Cr-0.15 Cr18 Cr24 Cr
Cash from investing-2 Cr-4 Cr-14 Cr-10 Cr-38 Cr-15 Cr8 Cr-10 Cr-40 Cr-100 Cr
Cash from financing-0.04 Cr5 Cr17 Cr2 Cr2 Cr7 Cr-0.72 Cr9 Cr13 Cr82 Cr
Net cash flow-0.45 Cr2 Cr3 Cr-5 Cr10 Cr-2 Cr10 Cr-0.88 Cr-9 Cr6 Cr
Free cash flow (OCF − Capex)-0.21 Cr-2 Cr-19 Cr-7 Cr10 Cr-2 Cr-1 Cr-0.15 Cr18 Cr-76 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %-9.1%5.4%6.8%1.7%4.1%6.7%9.8%12.2%15.8%12.1%
ROE %-8.8%4.6%3.1%0.7%2.8%5.3%6.9%8.3%13.3%10.9%
Debtor days18614886109122132142149156186
Inventory days90383668362810185334
Days payable1971063387539238200118186232
Cash conversion cycle79808990-381-79-485022-13
OCF / EBITDA %—31.4%4.1%n.m.883.7%55.8%14.7%-0.6%55.8%65.5%
OCF / EBITDA % (3 years)——26.5%45.6%402.5%351.6%163.8%15.8%27.3%44.8%
Debt / equity0.00680.00820.080.110.120.150.150.180.250.32
Current ratio4.154.223.232.541.101.651.842.272.061.83
Net debt / EBITDA——0.2249.890.441.000.130.531.261.99